Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pemetrexed

FDA-approved product (solution, intravenous), marketed as Pemetrexed, Pemfexy, Axtle and 3 more.

Registered studies
50+
Lab records
6
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Pemetrexed
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adenocarcinoma
  • Cancer
  • Large cell lung carcinoma
  • Lung large cell carcinoma
  • Malignant Mesothelioma
  • Malignant peritoneal mesothelioma
  • Malignant pleural mesothelioma
  • Mesothelioma
  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Folic acid analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA35.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli13.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae28.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis48.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • E. coli: measured active in 2 of 6 lab records
Open Pemetrexed in ChEMBL Registered studies below
Show the 6 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pemetrexed with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

    NCT06110663 · start 2023-12-30

    Registered record
    Registry ID
    NCT06110663
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    HS-10241+ Almonertinib; Pemetrexed + Cisplatin /Carboplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2023-12-30
    Completion
    2025-02-28
    Enrolment
    314

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionHS-10241+ Almonertinib; Pemetrexed + Cisplatin /Carboplatin
    PhasePhase 3
    Registry statusUnknown

  • Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

    NCT05746481 · start 2023-08-10

    Registered record
    Registry ID
    NCT05746481
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    Tiragolumab; Atezolizumab; Pemetrexed; Carboplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2023-08-10
    Completion
    2025-11-08
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    InterventionTiragolumab; Atezolizumab; Pemetrexed; Carboplatin
    PhasePhase 2
    Registry statusTerminated

  • Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer

    NCT05978401 · start 2023-08-10

    Registered record
    Registry ID
    NCT05978401
    Conditions
    Advanced Non-Small Cell Lung Cancer
    Interventions
    GLS-012+GLS-010; GLS-012+GLS-010; GLS-012+GLS-010+pemetrexed+carboplatin; GLS-012+GLS-010+paclitaxel+carboplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2023-08-10
    Completion
    2026-04-01
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Non-Small Cell Lung Cancer
    InterventionGLS-012+GLS-010; GLS-012+GLS-010; GLS-012+GLS-010+pemetrexed+carboplatin; GLS-012+GLS-010+paclitaxel+carboplatin
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients

    NCT05751187 · start 2023-06-27

    Registered record
    Registry ID
    NCT05751187
    Conditions
    Non-squamous NSCLC
    Interventions
    Pembrolizumab; Bevacizumab; Pemetrexed; Cisplatin; Carboplatin; Folic acid 350-1000 μg; Vitamin B12 1000 μg; Dexamethasone 4 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-06-27
    Completion
    2027-12-30
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-squamous NSCLC
    InterventionPembrolizumab; Bevacizumab; Pemetrexed; Cisplatin +4 more
    PhasePhase 2
    Registry statusActive not recruiting

  • A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma

    NCT05335941 · start 2023-06-13

    Registered record
    Registry ID
    NCT05335941
    Conditions
    Urothelial Carcinoma; Metastatic Cancer
    Interventions
    Pemetrexed; Zimberelimab; Etrumadenant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-06-13
    Completion
    2027-09-30
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrothelial Carcinoma; Metastatic Cancer
    InterventionPemetrexed; Zimberelimab; Etrumadenant
    PhasePhase 2
    Registry statusActive not recruiting

  • Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations

    NCT05299125 · start 2023-05-24

    Registered record
    Registry ID
    NCT05299125
    Conditions
    Metastatic Non-small Cell Lung Cancers
    Interventions
    Amivantamab; Lazertinib; Pemetrexed 500 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2023-05-24
    Completion
    2025-11-21
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Non-small Cell Lung Cancers
    InterventionAmivantamab; Lazertinib; Pemetrexed 500 mg
    PhasePhase 2
    Registry statusCompleted

  • A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    NCT05741021 · start 2023-03-01

    Registered record
    Registry ID
    NCT05741021
    Conditions
    Non-small Cell Lung Cancer; NSCLC; PD-1
    Interventions
    F520; Pemetrexed; Carboplatin; Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-03-01
    Completion
    2024-10-25
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer; NSCLC; PD-1
    InterventionF520; Pemetrexed; Carboplatin; Paclitaxel
    PhasePhase 2
    Registry statusUnknown

  • Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

    NCT05609578 · start 2022-11-22

    Registered record
    Registry ID
    NCT05609578
    Conditions
    Advanced NSCLC; Metastatic Lung Cancer
    Interventions
    Adagrasib oral dose of 400 mg twice daily tablets; Pembrolizumab; Chemotherapy: Pemetrexed; Cisplatin/Carboplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2022-11-22
    Completion
    2026-12-01
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced NSCLC; Metastatic Lung Cancer
    InterventionAdagrasib oral dose of 400 mg twice daily tablets; Pembrolizumab; Chemotherapy: Pemetrexed; Cisplatin/Carboplatin
    PhasePhase 2
    Registry statusActive not recruiting

  • A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors

    NCT06116240 · start 2022-09-02

    Registered record
    Registry ID
    NCT06116240
    Conditions
    Solid Tumor
    Interventions
    TQB2450 injection; AL2846 capsule; Pemetrexed disodium for injection; Cisplatin injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2022-09-02
    Completion
    2023-12
    Enrolment
    135

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor
    InterventionTQB2450 injection; AL2846 capsule; Pemetrexed disodium for injection; Cisplatin injection
    PhasePhase 1
    Registry statusUnknown

  • Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIA-IIIB Resectable NSCLC (FORESEE)

    NCT05430802 · start 2022-02-24

    Registered record
    Registry ID
    NCT05430802
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    Furmonertinib+cisplating/pemetrexed
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2022-02-24
    Completion
    2029-12-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    InterventionFurmonertinib+cisplating/pemetrexed
    PhasePhase 2
    Registry statusActive not recruiting

  • (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

    NCT05153408 · start 2022-01-13

    Registered record
    Registry ID
    NCT05153408
    Conditions
    Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Neoplasms; Neoplasms by Site; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms by Histologic Type; Neoplasms, Nerve Tissue; EGFR C797S; EGFR C797A; EGFR L858R; EGFR Exon 19 Deletion; EGFR Gene Mutation; EGF-R Positive Non-Small Cell Lung Cancer; EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance; EGFR Activating Mutation; Thoracic Neoplasms; Antineoplastic Agents; Protein Kinase Inhibitors; EGFR C797G; EGFR C797X; Non Small Cell Lung Cancer
    Interventions
    BLU-701; osimertinib; carboplatin; pemetrexed
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2022-01-13
    Completion
    2022-12-09
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Neoplasm; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Neoplasms +23 more
    InterventionBLU-701; osimertinib; carboplatin; pemetrexed
    PhasePhase 1
    Registry statusTerminated

  • A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

    NCT05067283 · start 2021-12-17

    Registered record
    Registry ID
    NCT05067283
    Conditions
    Advanced Solid Tumors
    Interventions
    Calderasib; Pembrolizumab; carboplatin; pemetrexed; cetuximab; oxaliplatin; leucovorin; 5-fluorouracil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2021-12-17
    Completion
    2030-02-25
    Enrolment
    830

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumors
    InterventionCalderasib; Pembrolizumab; carboplatin; pemetrexed +4 more
    PhasePhase 1
    Registry statusRecruiting

  • Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer

    NCT04702009 · start 2021-01-20

    Registered record
    Registry ID
    NCT04702009
    Conditions
    Advanced Lung Carcinoma; Non-small Cell Lung Cancer
    Interventions
    Chemoimmunotherapy (CIT): Sintilimab + Platinum-Based Doublet Chemotherapy; Chemoimmunotherapy (CIT): Sintilimab + Platinum-Based Doublet Chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2021-01-20
    Completion
    2026-01-20
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Lung Carcinoma; Non-small Cell Lung Cancer
    InterventionChemoimmunotherapy (CIT): Sintilimab + Platinum-Based Doublet Chemotherapy; Chemoimmunotherapy (CIT): Sintilimab + Platinum-Based Doublet Chemotherapy
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance

    NCT04316351 · start 2020-04-01

    Registered record
    Registry ID
    NCT04316351
    Conditions
    IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy
    Interventions
    Toripalimab + Pemetrexed + Anlotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-04-01
    Completion
    2022-04-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy
    InterventionToripalimab + Pemetrexed + Anlotinib
    PhasePhase 2
    Registry statusUnknown

  • KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

    NCT04165070 · start 2019-12-19

    Registered record
    Registry ID
    NCT04165070
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    Pembrolizumab; Carboplatin; Paclitaxel; Pemetrexed; Vibostolimab; Boserolimab; MK-4830; MK-0482; Ifinatamab Deruxtecan (I-DXd); HER3-DXd
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2019-12-19
    Completion
    2032-10-13
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionPembrolizumab; Carboplatin; Paclitaxel; Pemetrexed +6 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting